Note: Descriptions are shown in the official language in which they were submitted.
- ~Z~ 5
--1--
HAEMOP~IILUS INFLUENZAE B
POLYSACCHARIDE EXOTOXOID CONJUGATE VACCINE
The invention relates to a new Haemophilus
influenzae b polysaccharide-exotoxoid, exemplified by a
polysaccharide-diphtheria toxoid conjugate (PRP~D)
vaccine and polysaccharide-tetanus toxoid conjugate
(PRP-T) vaccine, the polysaccharide haptens used for
making same and the process for producing them. The
invention provides a pure Haemophilus influenzae b
1~ polysaccharide, adjusted by heat treatment to a
molecular size principally between 200,000 and 2,000,000
dalton, consisting of approximately equimolar amounts of
ribose, ribitol and phosphate which is then activated
with an activator, typically cyanogen bromide~
15 Molecular sizes stated in this application are
referenced to dextran standards by gel permeation
chromatography. The activated polysaccharide is
intimat~ly mixed with an exotoxoid, preferably
diphtheria toxoid, to effect conjugation. Preferably,
20 ~he exotoxoid is derivatized using as a spacer a bridge
of 4 to 8 carbons, e.g.~ the adipic acid hydrazide
derivative of diphtheria toxoid (D-AH). Alternate
d~rivatized exotoxoids which can be used include tetanus
toxoid, (T-AH)o The exotoxoid is attached to multiple
25 AH units.
By use of this method there is obtained a conjuyate
vaccine which elicits a T-cell dependent response to
polysaccharide from Haemo~hilus influenzae b.
Such a conjugate is especially valuable for use in
3~ prevention of Haemophilus infections in infants and
- young children.
The invention also makes available a conjugate
vaccine useful for immunization against diseases such as
diphtheria and tetanus. The potency in humans of such
conjugates is greater than that of the conventional
diphtheria and tetanus toxoid preparations. The method,
~`.
~2~ S
by careful control and removal of excess activator,
provides a polysaccharide conjugate constructed of
multiple molecules of exotoxoid at-tached to single
molecules of polysaccharide, linked through a spacer,
and substantially free from cross linked or polymeric
derivatives. The formula may be generally represented
as PRP-Xn wherein X is the toxoid moiety and n is an
integer smaller than 20, a typical average being 7-8.
(The diphtheria ~oxoid conjugate is referred to herein
as PRP-D, the tetanus conjugate as PRP-T without use of
the integer n).
The development of stable humoral immunity requires
the recognition o~ foreign material by at least two
separate sets of lymphQcytes. These cets are the
B-lymphocytes, which are the precursors of antibody
forming cells, and the T-lymphocytes which modulate the
function of B-cells. While some antigens, including
several polysaccarides, are capable of directly
stimulating B--cells to produce antibodies (T-independent
antigens), most antigens (T-dependent) must be presented
to the B-cell by a T-lymphocyte. In the case of the
vaccines of this invention, the exotoxoid portion of the
vaccine is recognized by the T-cell system. Since the
protein carries both its own antigenic determinants and
the covalently bound PRP hapten, both sets of deter-
minants should be presented by T-cells to B-cells. The
result o administration o this carrier-hapten
conjugate preparation is that PRP is presented as a
T-dependent immunogen. A T-dependent presentation of
PRP induces protective immunity in infants, the target
population at greatest risk. The conjugate vaccines of
,...
~.2~ 95
--3--
this invention are therefore of special value in small
infants. Administration of such conjugate to women
induces a high proportion of IgG antibody to the vaccine
antigens, which penetrates the placental barrier during
pregnancy, and thus affords protection to the infant
from birth.
T-independent antigens induce B-cells to terminally
differentiate into antibody secreting cells (plasma
cells~, while T-dependent responses are considerably
more complex. After receiving a T-dependent stimulus,
the B-cell population enters not only antibody
production, but also proliferation and maturation.
There results an increase in the number of B-cells
making antibodies to PRP and an increase in the number
of B-cells capable of responding to a second exposure to
PRP. Repeated immunization results in further increases
in the number of PRP specific B-cells and, consequently,
higher antibody titers, a booster response. In summary,
while T-independent responses are limited by the number
of responsive B-cells, T-dependent responses result in
an increase in the total number of antigen responsive
cells.
The PRP-exotoxoid vaccine of this invention has
been shown to function as a T-dependent immunogen in
laboratory animals. All animals in a group of rabbits
serially immunized with a standard dose of PRP-D showed
booster responses. In addition, primary immunizations
with the carrier proteins used in the conjugate, e.g.
diphtheria toxoid for PRP-~, were shown to augment the
initial response to the PRP component of the
PRP-exotoxoid conjugate. A similar augmentation of the
PRP response was not seen in anima]s primed with an
exotoxoid other than that used in the conjugate.
The vaccine of this invention is a PRP-exotoxoid
hapten-carrier conjugate. In such vaccines, the
antigenic but weakly immunogenic hapten molecule (PRP)
contributes a new antigenic specificity to highly
--4--
immunogenic carrier molecules such as diphtheria (D) or
tetanus toxoid (T).
The purified diphtheria toxoid (D) used as carrier
in the preparation is a commercial exotoxoid modified
(derivatized) by the attachment of a 4-8 carbon spacer
molecule, such as adipic acid dihydrazide (ADH), using
the water-soluble carbodiimide condensation method. The
modified exotoxoid, typically the adipic hydrazide
derivative X-AH, is then freed from unreacted ADH. This
is a soluble product, substantially free of
cross-linking which is verified by lack of a substantial
increase in molecular size as determined by gel
chromatography and polyacrylamide gel electrophoreis.
The capsular polysaccharide of Haemophilus
influenzae b is prepared from commercial sources such as
used for licensed polysaccharide vaccines and is
obtainable from Connaught Laboratories. However, while
the polysaccharide is conventionally purified as a
calcium salt, the use of calcium ions is avoided because
they interfere with the use of carbonate buffer in the
conjugation procedure. The molecular size of the
polysaccharide is then ad~usted by heating until the
desired dimension for the hapten is obtained.
Typically, heating of the liquid polysaccharide for 15
minutes at 100C suffices to assure that less than 20%
of the molecules are of a molecular size smaller than
200,000 dalton an~ less than 20~ of a molecular size
greater than 2,000,000 dalton. This sizing operation is
important to obtain a proper PRP-D or PRP-T conju~ate.
The sized polysaccharide thus obtained is activated
with an activator to create an electrophilic group on
the polysaccharide such as a cyanogen halide or sodium
borohydride. A typical activator used is cyanogen
bromide. Unreacted activator is exhaustively removed
because, if there is a substantial residue, it causes
cross-linking of the protein in the following reaction
--5--
mixture. The resulting cross-linked product traps
polysaccharide, producing a lower yield of vaccine and a
higher molecular size conjugate differing in chemical
properties and solubility from the conjugate produced
herein and a vaccine which lacks the desirable
proportion of the vaccine of this invention.
The activated PRP and X-AH are then combined and
allowed to react in the cold. Some of the hydrazide
groups on the derivatized exotoxoid react with the
activated sites on PRP to form covalent bonds. The
product is PRP covalently bound to derivatized exotoxoid
through a 4-8 carbon bridge. This reaction product is
purified by gel permeation chromatography to remove any
unreacted protein and low molecular size contaminants.
The typical molecular slze of the principal fraction is
about 675,000 dalton relative to dextran standard. A
typical range for relative molecular size is 140,000
dalton to 4,50~,000 dalton.
A preservative such as thimerosal is added, in the
case of thimerosal to a inal concentration of 1:10,000.
The bulk concentrate is filtered through a 0.2 micron
membrane filter and stored in the cold.
The PRP- exotoxoid conjugation product is heat
resistant and water soluble. The lack of cross-linking
is verified by lack o a substantial increase in
molecular size from that of the starting poeysaccharide
as determined by gel permeation chromatography and by
polyacrylamide gel electrophoresis. H~at stability
assures a long shelf-life and a stable product even in
unfavorable climates~
The reaction can be represented schematically as
two steps;
(1) PRP + CNBr ~ PRP*
(2) PRP* + nX i PRP¦~X1n
If the cyanogen halide removal is not efficiently
carried out, there occur besides conjugation o the
activated PRP and exotoxoid to form PRP (-X)n, such
6~S
--6--
undesirable reactions as formation of X-X or multiply
linked derivatives, e.g.,
PRP ~ CNBr--~nX + %X P~P X
~X -X -PRP
A typical human dose of PRP-exotoxoid conjugate
vaccine for subcutaneous or intradermal injection
consists of 0.5 ml containing 10 micrograms of ribose or
the approximate equivalent of 40 micrograms of the
conjugate product. Ampoule solutions are prepared by
dilution of the bulk concentrate with phosphate buffered
saline solution using thimerosal as a preserva~ive.
The product induces antibody formation in humans to
both the PRP and exotGxoid component.
The following examples are provided for purposes of
illustrating tha invention in further detail. They are
not to be construed as limiting the invention in spirit
or in scope.
In Example V below, reference is made to the accompany-
ing drawing, wherein-
Figure 1 demonstra~es the immunogenicity of
influenzae b capsular polysaccharide i e
the anti-PRP response.
. . .
EXAMPLE I: Preparation of PRP
A Or~anlsm
.
Capsular polyribosyl ribitol phosphate (PRP) of
Haemo~ilus influenzae b was prepared from the Eagan
strain. The culture was repeatedly transferred and a
lyophilized seed prepared. From this lyophilized seed
one additional transfer was made to prepare wet working
seeds (stored at -6QC)~ Fermenter lots of bacterial
cells were prepared from the wet working seed.
Culture purity is determined by the following
criteria:
1. nega~ive Gram stain characteristics;
s
6~
2. growth on agar containing NAD
(diphosphopyridine nucleotide~ and Hemin
(Bovine Type I crytalline salt of
ferriheme);
)69~
., ,
-7
3. failure to grow on agar without NAD or
Hemin; and
4. agglutination by specific antisera (type b
Haemophilus influenzae b, Hyland
Laboratories).
B~ Cultivation and Media
For subculturing the bacterium, i.e., preceding
inoculation of a fermenter, BHI Agar (per l.iter: 37 gm
BHI Difco, 15 gm Bacto Agar Difco, 0.6 ml 1% NAD
Sigma-~rade III and 6 ml of 0~2% Hemin (Sigma-Bovine
Type 1) was employed. Cells (20 hours) washed from an
agar surface are used to inoculate Haemophilus
influenæae b (Hib) liquid media (1 liter aliquots);
.
these cultures are incubated with shaking until the
bacterium reaches the log phase of its growth cycle. At
this time, 2 liters of culture are used to inoculate
each 40 liters of liquid Hib media in a fermenter and
300 ml 8% UCON* (Union~Car~ide lubricant) is added.
After 16 to 18 hours, th~ fermenter culture is ready for
2l~ harvest.
The composition of the ~ib liquid media per 1000 ml
is:
Yeast Extract Dialysate, Difco 5.0 gm
Casamino Acids, Difco 22.5 gm
Sodium Phosphate, dikasic 14.4 gm
Dextrose 559 ~m
Hemin 20 gm
Ammonium Hydroxide (30%) O.1534 ml
NAD 1% 0.6 ml
When harvesting a fermenter~ culture purity is
detPrmined by appropriate Gram staining and culturing
techniques (see A 1-4 above). Cetavlon
~hexadecyltrimethylammonium bromide) is added to the
culture to a final concentration of 0.1%. After 30
minut~s~ at which time the bacteria have been inacti-
vated, the solid paste is collected by centrifugation.
The wet paste is stored at -70C until further
processing.
* - Trademark
~; ,,
--8--
C. Purified Pol~saccharide
The e~traction and subsequent purification of khe
PRP is carried out using -the following procedure:
1 Dissociation from Deter~ent
For each gram wet weight of paste, 10 ml of 0.4 M
NaCl is added. The suspension is mixed in a commercial
blender for 30 seconds. The mixture is centrifuged for
minutes at 17,000 Xg in the cold (4C). The
supernatant is collected and ethanol is added to a
concentration of 25~. This material is then centrifuged
for 2 hours at 17,000 Xg (4C) and the supernatant
~aved. Ethanol, at four times the volume of the
supernatant, is added and the material held overnight at
4C.
2. Removal of Nuclelc Acids
The material is centri~uged for 5 minutes at
2800 ~g (4C). The sediment is collected and
resuspended in Tris-MgSO4 buffer at one-fourth the
volume originally used to extract the paste. The
composition of the Tris buffer is as follows per liter
of distilled water-
tris~hydroxymethylamino-methane (Sigma) 6 gm
Mg~O4 . 7 H2O 246 mg
thimero~al (Elanco) 50 mg
The p~ is adjusted to 7.0 ~ 0.2 with concentrated
hydrochloric acid.
Deoxyribonuclease I 1.5 mg (Sigma D-0876) and
ribonuclease-A 0.75 mg (Sigma-Type 1-AS, R-5503) per 100
gm of origlnal wet paste are added. The material is
placed in a dialysis bag and incubated for 18 hours at
37C versus 18 liters of Tris-MgSO4 buffer.
3. Removal of Proteins
The material is further processed to remove protein
components by adding an equal volume of phenol-acetate
solution (135 ml of 10 p~rcent (w/v) sodium acetate
combined with 454 gms of phenol). The material is then
~o2~g6~5
_9_
shaken for 30 minutes (4C), centriuged for 15 minutes
at 17,000 Xg and the aqueous phase collected. Two
additional phenol extractions are conducted followed by
dialysis of the last aqueous phase versus distilled
water.
The material at this stage constitutes the bulk
liquid capsular polysaccharide (PRP) and is stored at
-20C until further processing (Section D below).
4. Assessment of Quality of Pol~saccharide
The quality of the bulk PRP is judged based on the
analysis of a liquid sample that is removed. Ethanol is
added (4 volumes), then CaC12 (final concentration of
0.02~) and the PRP is precipitated. The PRP is
sedimented by centrifugation and dried under vacuum over
a dessicant. A thermogravimetric analysis (TGA) is used
to determine the moisture content. Further analyses are
calculated on a dry weight basis.
Criteria for acceptance include:
(a) analysis of ribose (Orcinol method): greater
than 30 percent,
(b) analysis of protein (Lowry method): less
than 1 percent,
(c) analysis of nucleic acids (U.V. adsorbance):
less than 1 percen~, and
(d) precipitation with specific immune sera
(counterimmunoelectrophoresis method).
In addition, the molecular size is determined by
suitable gel premeation chromatography. The
polysaccharide is monitored for endotoxin by Limulus
Lysate testing and by rabbit pyrogenicity testing.
A typical lot has the following characteristics:
(a) Protein content, 0.5%
(b) Nucleic acid content, 0.35%
(c) Residual bovine antigens: No contamination
of the purified PRP by bovine RNA-ase and
DNA-ase used in preparation of the
6~
-10--
polysaccharide, as measured by
radioimmunoassay.
(d) Endotoxin content was measured by the
Limulus Amoebocyte to Lysate Assay (LAL):
200 ng/mg PRP.
(e) Kd on CL-4B Sepharose: 0.30. A value of
0.30 corresponds to an approximate molecular
weight of 1,125,000 relative to dextran
standards.
D Pre~aration of Polysaccharide (PRP) Reagent
.
The polysaccharide is thus puri~ied as a liquid,
but calcium is not used in the purification procedure.
(Conventional polysaccharide purification yields a
calcium salt, but calcium can combine with the carbonate
buffer used hereinbelow during conjugation to form a
precipitate.)
The size of the polysaccharide is adjusted by
heating at 100C for a time proportional to the degree
of size change needed. Size of the polysaccharide is
adjusted so that less than 20% elutes from a CL-4B
Sepharose column in the void volume, and less than 20%
elutes with a Kd greater than 0.5. The principal frac-
tion has a molecular size of 200,000 to 2,000,000
dalton.
EXAMPLE II. Activation of PRP
_
A. This polysaccharide is cooled on an ice bath to
4C in a reaction vessel equipped with a magnetic
stirrer. The initial volume of PRP at the concentration
of 25 mg/ml (20-30 mg/ml range) in distilled water is
recorded. Then sodium chloride is added to a
concentration of 0.85%.
B. The pH of the resulting solution of the sodium
salt of the polysaccharide is raised to 10.5 11.0 by
addition of lN sodium hydroxide. (This range is chosen
because at a lower p~ there is less reaction with
cyanogen bromide and at higher pH the polysaccharide
breaks down.)
~%~
--ll--
C. Dry cyanogen bromide is dissolved in 0.005N
sodium bicarbonate buffer of pH 10.5-11.0 and
immediately (within 10 minutes of preparation) is added
to the reaction vessel in a proportion of 0.4 mg/mg PRP.
D. The pH of the mixture is adjusted to and
maintained at 10.5 11.0 for 6 minutes by addition of
sodium hydroxide.
E. The pH is then dropped to 6.0 with lN HCl.
(Acid pH stabilizes the activated sites created on the
polysaccharide by cyanogen bromide. Lowering the pH
further results in hydrolysis of the PRP.)
G. There is added an equal volume of saline, pH
6.0, pre-chilled to 4C.
H. The cyanogen bromide-polysaccharide mixture is
trans~erred to a concentrator apparatus and concentrated
to the initial volume recorded at step A~
I. Steps G and H are repeated at total of 10 times.
Thus about 99.9~ of the unconsumed cyanogen bromide is
removed while the polysaccharide concentration is
maintained at 25 mg/ml. If the cyanogen bromide is not
removed, it reacts with the diphtheria exotoxoid used
below.
EXAMPLE III. Preparation of D-AH Carrier
A. Commercial diphtheria exotoxoid ~D) in distilled
water is concentrated to 20-~0 mg/ml, typically 35 mg/ml
over a membrane that retains molecules over 10,000
dalton in a positive pressure stirred concentrator.
B. A dry mixture of 8 mg adipic acid dihydrazide
(ADH) per mg protein and 0.75 mg
l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) per
mg protein are placed in a reaction vessel equipped with
an efficient stirrer and a pH probe to permit monitoring
and control of pH.
C. The diphtheria exotoxoid is then added to the
reaction vessel making the proportion of the reactants:
diphtheria exotoxoid = 35 mg protein/ml
ADH = 8.0 mg/mg protein
~Z~q~6~5
,, ~
-12-
EDAC = 0.75 mg/mg protein
(The use of acetate buffer on sequential addition
of ADH and EDAC results in a persistent flocculent
precipitate. The reactants ha~e a sufficien'c buffering
capacity of their own.)
D. The pH is immediately adjusted to 4.7 and
maintained at 4.7 ~ 0.2 for a minimum of 2 hours.
1. The course of the chemical reaction can be
followed on the recorder of the pH
controller. If necessary, the reaction is
allowed to proceed past 2 hours until the pH
is stable for at least lS minutes, (i.e., 15
minutes without needing HCl addition to
control pH).
2. The amount of HCl consumed is recorded as a
process check.
3. Temperature change in the reaction vessel is
also monitored.
E. The reaction product is dialyzed at 4C against
two changes of saline, a minimum of 100 volumes and 8
hours per change.
F. It is then dialyzed against two changes of
phosphate buffered saline, minimum volume, time and
temperature as for step E.
G. The product (D-AH) is concentrated back to 25
mg/ml protein with a positive pressure apparatus and
lQ,OOO MW membrane.
H. The concentrate is sterile filtered (0.2 ~ and
stored at 4C~
Assay of a sample of a typical lot of such D-AH
carrier showed a ratio of 38.3 microgram ADH/mg DT.
Chromatography of that sample showed a Kd value on CL-4B
Sepharose of 0.75 which corresponds to an approximate
molecular weight of 139,000 relative to protein
standards~
~21~
-13-
EXAMPLE IV. Formation of the Covalent
Polysaccharide-di~heria Toxoid Conju~ate ~PRP-D)
A. The diphtheria toxoid adipic acid hydrazide
carrier (D-AH) of Example III, at a concentration of 25
mg/ml, is treated with sodium bicarbonate to a
concentration of 0.5M and the pH is adjusted to 8.5.
(Significantly lower salt concentrations result in the
formation of a gel in the final reaction mixture with
activated polysaccharide.)
B. In a reaction vessel which can be sealed, an
equal amount of the washed PRP solution produced in
Example II is added and the pH should be stable at
8.4 8.6. (If CNBr has not been removed, the pH will
drift rapidly downward and a copious precipitate will
form. This reaction occurs even in the absence of
polysaccharide. There should not be a significant
change of the physical appearance of the reactants on
combination.)
C. The reaction mixture is tumbled for 15-18 hours
at 4C.
D. The conjugate is purified by gel permeation
chromatography on Sephacryl-300 equilibrated in
phosphate buffered saline to remove unreacted proteln
and material of molecular size less than 140,000 dalton
in size. (If the starting polysaccharide is too small
it ~ill not be possible to separate the conju~ate from
ree protein in this manner.)
E. Samples of this purified conjugate are removed
for chemical analysis, described in the following
section of this example.
F. Thimerosal is added to the purified conjugate to
a concentration of 1:10,000 and the product is stored at
4C until analysis.
G. The product is 0.2 micron sterile iltered. (If
the polysacharide is not sized as described in Example
I(D), i.e., if it is oversize, the resulting conjugate
will not be filterable.)
.
-14~
Analysis
Tests performed on the bulk concentrafe of ExampIe
IV gave the following results:
a) Ribose content: 156.5 microgram/ml.
(For the calculation of PRP values in Example V,
a conversion factor of 2 is used to calculate a nominal
polysaccharide concentration based on the empirically
determined ribose concentration.)
b) Protein content: 330 microgram/ml.
c~ Ribose/protein ratio: 0.47 (limits 0.25-1.0)
d~ Chromatographic analysis on Sepharose*CL-2B
gave the chromatographic profile which shows a
homogeneous distribution of conjugate molecules as a
single peak.
e) Kd (polysaccharide): 0.36 using sepharose
Cl-4B, 0.77 using Cl-2B.
Determined by individual fraction ribose assay
for PRP. A value of 0 ~6 on Cl-4B corresponds to an
approximate molecular size of 674,000 relative to
dextran standards.
f~ Kd (protein~: 0.34 u~ing C1-4B; 0.71 using
Cl-2B~
Determined by individual fraction Lowry assay
for protein. The change in the Kd value of the
diphtheria exotoxoid from 0.75 to 0.34 on Cl-4B shows
that the conjugation of protein with polysaccharide
form~ a molecule which is chromatographically different
from either raw material.
g) Free Protein~ Less than 5%.
Free protein represents derivatized diphtheria
carrier protein which as not been bound to PRP. It is
determined by comparing the amount of protein that
elutes in the position of a diphtheria exotoxoid sample
relative to the total eluted protein~
h) Endotoxin Content: 1 ug/ml
Endotoxin was quantitated by the Limulus
Amoebocyte to Lysate ~ssay (LAL). The endotoxin content
amounts to 64 ng per 10 ug ribose human dose of PRP-D.
* - Trademark
~.2~ 36~
-15-
i) Pyrogenicity:
The bulk concentrate meets the United States
standards for non-pyrogenicity using a weight equivalent
(human) dose of 0.15 ug ribose per milliliter per
kilogram body weight of rabbit.
j) Polyacrylamide Gel Electrophoresis (PAGE):
~ AGE analysis was performed to obtain supporting
evidence of purity and covalent bonding between
polysaccharide and protein. While free carrier bands
just over halfway into the rod gel, at approximately the
position of catalase (60,000 MW), the PRP-D conjugate
was not able to enter the gel (prior to the position of
thyroglobulin, 330,000 MW). PRP-D showed a single band
at the origin.
k) Cyanogen Bromide:
While cyanogen bromide (CNBr) is used in the
first steps before preparing a PRP-D conjugate, it is
subsequently excluded from the product. Several steps
of the process contribute to the reduction of CNBr
content. However, final purification of the vaccine by
gel permeation chromatography removes any contaminants
below 100,000 MW. This purification precludes
contamination with residual traces of free CNBr or its
degradation products.
1) Heat Stablility: A study or hea-t resistance
of PRP-D conjugate vaccine was performed. The bulk
material was concentrated 40 fold and three 3ml samples
were taken. The first was kept at 4C water bath for 16
hours, and the third was heated in a 100C water bath
for 30 minutes. The tests performed were for protein
and ribose content, gel permeation chromatography with
sepharose Cl-4~ and SDS-polysaccharide gel
electrsphoresis (PA&E).
The results showed no significant change in ribose
or protein content between the samples compared to the
results in tests (a) and (b) above. The chromatographic
analyses showed a minor decrease in the molecular size
~2~ 35
-16
of the conjugate material as conditions were made
increasingly harsh. However, upon fractional analysis
of these samples by measuring absorbance at 254 nm, the
material maintained only one peak coinciding with the
polysaccharide peak and no free protein peak appeared;
the results are thus comparable to those in (d) and (g)
above. This demonstrates that the linking between the
protein and polysaccharide did not break but the
decrease in molecular size was due to the breaking of
bonds within the linear polysaccharide. This was
further demonstrated by comparison of PAGE analysis of
these samples to the results described under (j) above,
free protein was not detec~able in any of the samples
even in the presence of a detergent ~sodium dodecyl
sulfate). This strongly affirms the covalency of the
derivitized protein-polysaccharide linkage and its
stability through high temperature treatment.
EXAMPLE V. PRP-D Immunogenicity Testing
This experiment was designed to show T-cell
dependency as evidenced by: carrier dependency, carrier
specificity, booster effect, and change in Ig class.
This experiment was carried out in two parts: 1) an
initial priming sequence of two injections; 2) a
challenge sequence of two injections.
Materials:
1, PRP-D Bulk concentrate, Example 4.
2. Tetanus Toxoid (T).
3. Diphtheria Toxoid (D).
4. H. influenzae b capsular polysaccharide (PRP).
5. PRP/D, a mixture of 20 ug PRP (10 ~g ribose) and
20 ~g D.
6~ PRP/D-AH, a mixture of 20 ,ug PRP (10 ~g ribose)
and 20 ug D-AH.
~z~
-
-17-
Method_
All immunizations were administered subcutaneously
without adjuvant in 1 ml volumes. All doses containing
PRP were adjusted to 10 ug ribose per 1 ml dose.
Unconjugated exotoxoid doses were adjusted to 20 ug
protein per 1 ml dose. A rotating schedule was used
with immunizations spaced 14 days apart. Each
immunization was followed by a bleed lO days later. All
preparations were diluted in phosphate buf~ered saline
containing 0.01% thimerosal. Aliquots were prepared as
four dose vials, and stored at -20C. Three rabbits
were immunized in each group.
Serology:
Sera were assayed by the solid phase
radioimmunoassay (SPRIA~ for anti-PRP, anti-D-AH,
anti-D, and anti-T as indicated. Antibodies levels were
quantitated as microgram IgG and IgM per ml.
P _ ocol:
SPRIA
Grou~ Primary Secondary PRP DT-AH DT TT
1 PRP PRP +
2 T PRP-D + + + +
3 D PRP-D + + +
4 PRP/D PRP/D + +
PRP/D-AHPRP/D-AH + +
6 PRP-D PRP-D + + +
Schedule:
Rabbits were pre-bled and immunized according to
group every 14 days. Each immunization was followed by
a post-bleed 10 days later. The first two injections
were made with the primary immunogen, while the third
and fourth injections were made with the secondary
immunogen.
Anti-PRP response is demonstrated in Figure 1. The
mean level o~ IgG antibody to Haemophilus influenzae b
-18-
capsular polysaccharide in the six experim~ntal groups
of rabbits (three animals per group) are graphicially
illustrated. Groups are labelled on this figure in
accordance with the above protocol. Prebleed levels
were less than 1 ~g/ml for all rabbits and are not shown
in this figure for clarity.
Open bars represent the level of IgG following two
successive injections with the primary immunogen. Solid
bars show the IgG levels following the third and fourth
injections which were with the secondary or challenge
immunogens.
IgG responses were seen only following immunization
with the PRP-D conjugate vaccine. Priming the rabbits
in group 3 with diphtheria toxoid accelerated the
response to PRP-D, while priming the tetanus toxoid
(group 2) had no effect.
TETANUS TOXOID
EXAMPLE VI. Preparation of T-AH Carrier and
Formation of Covalent
Polysaccharide-Tetanus Toxoid_Conjugate (PRP-T)
In the producedure of Example III, commercial
tetanus toxoid is used in the place of diphtheria toxoid
to produce the adipic acid hydrazide derivatlve.
Assay of a sample of a typical lot of T-A~ carrier
showed a ratio of 53.9 microgram ADH/mgT.
Chromatography of that sample showed a Kd value of CL-4B
Sepharose of 0.66 which corresponds to an approximate
molecular weight of 227,000 relative to protein
standards.
Polysaccharide conjugates with the adipic hydrazide
derivate of tetanus toxoid are formed using the same
procedures as for D-AH, as described in Example IV.
Analysis of a typical lot of PRP-T showed 142.6
micrograms of polysaccharide and 260 micrograms of
portein per ml. The conjugate was soluble and 0.2
micron filterable. When chromatographed on CL-4B the
6g5
--19--
protein component demonstrated a Kd of 0.30 and the
polysaccharide coMponent a Kd of 0.37.
-2~L
Table 1
ANTI-PRP RESPONSE
Solid Phase Radioimmunoassa for I~M and IgH
: : PRP : Diphtheria Toxoid : Tetanus Toxoid
: : IgG : IgM : IgG : IgM : IgG : IgM
-
Group 1 Pre 0.0 0 ND ND
Post 1 0.33 0
0.58
P~st 2 0.8 0
-1.39
Post 3 0 0
Post 4 0 0
Grou~ 2 Pre 0 0 0 0 0.5 0
'0.87
Post 1 0 0 0 0 25.1 113.1
'-15.10 '-129.54
Post 2 0 0 0 0 112.00 44.60
0 36.gO
Post 3 -42 529 ,,45 55 0 0 ll.o.00 -14 752
Post 4 36.1 74.57 0 0 lSl 60 2 00
-17.43 -28.81 -52 64 '3 46
Gr~E~3 Pre 0.2 0 0 27.07 0.8 65.00
0.35 -46.88 -1.39 -112.58
Post 1 0.2 0 0 0 0.8 0
0.35 -1.39
Post 2 0 14.6 6.47 0 0.67 0
'25.29 -5.98 -0O59
Post 3 19.4 130.33 10.63 0 0.37 0
-13.4 '89.49 '8.08 '0.65
Po~t 4 74.2 82.63 29.03 0 1.30 0
-76.73 -5.16 -26.59 -2.25
Group 4 Pre 0 0 0 21.77 ND
-18.85
~ost 1 0 15.6 2.67 30.87
'27.02 0.85 -27.14
Post 2 0 0 37.2 26.2
"10.94 '24.30
-2~j-
Table 1 Cont'd
: : PRP : Diphthexia Toxoid : Tetanus Toxoid
: : IgG : IgM : IgG : ~ : I&G : IgM
Post 3 0 0 210.00 19.63
'0 '-17.06
Post 4 0 0 298.27 0
207.70
Group 5 Pre 0 0 ND
~ost 1 0 0
Post 2 0 0
Post 3 0 0
Post 4 0 0
Group 6 Pre 0 0 0 0
Post 1 -62 56 1851 4l
Post 2 54.2 182.00 0.93 0
-14.73 0 -1.62
Post 3 57 6 182.00 3.05 0
'22 91 0 -4.31
Post 4 39.6 91.20 5.95 0
-25.17 0 -8041
* IgG and IgM are expressed as ug antibody per ml of
serum. All value are mean and standard error.
# Ig levels below the sensitivity of the assay were
assigned a value of zero (O). If levels higher than the
range of the assay this were assigned a value equal to
the upper limit of the assay.
% ND = Not Done.
